| Puneet Bhullar, MD | |
|
615 Lilly Rd Ne Ste 200, Olympia, WA 98506 | |
| (360) 413-8413 | |
| (360) 413-7148 |
| Full Name | Puneet Bhullar |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 13 Years |
| Location | 615 Lilly Rd Ne Ste 200, Olympia, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184910861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD60731117 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Washington | 6709782600 | 393 |
News Archive
Out of a library with billions of artificial antibodies, researchers have identified ten that can possibly prevent cancer tumours from growing.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter's Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.
SeeChange Health, the nation's only fully-insured, value-based health insurance provider, announced today the acquisition of Central Benefits National Life Insurance, a health and life insurance company based in Westerville, OH. The transaction closed on July 31, 2009.
› Verified 9 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174744304 PECOS PAC ID: 6709782600 Enrollment ID: O20031211000028 |
News Archive
Out of a library with billions of artificial antibodies, researchers have identified ten that can possibly prevent cancer tumours from growing.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter's Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.
SeeChange Health, the nation's only fully-insured, value-based health insurance provider, announced today the acquisition of Central Benefits National Life Insurance, a health and life insurance company based in Westerville, OH. The transaction closed on July 31, 2009.
› Verified 9 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619176997 PECOS PAC ID: 7719873496 Enrollment ID: O20040227000744 |
News Archive
Out of a library with billions of artificial antibodies, researchers have identified ten that can possibly prevent cancer tumours from growing.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter's Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.
SeeChange Health, the nation's only fully-insured, value-based health insurance provider, announced today the acquisition of Central Benefits National Life Insurance, a health and life insurance company based in Westerville, OH. The transaction closed on July 31, 2009.
› Verified 9 days ago
| Entity Name | Olympia Obstetrics & Gynecology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922045848 PECOS PAC ID: 8426086802 Enrollment ID: O20050727000693 |
News Archive
Out of a library with billions of artificial antibodies, researchers have identified ten that can possibly prevent cancer tumours from growing.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter's Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.
SeeChange Health, the nation's only fully-insured, value-based health insurance provider, announced today the acquisition of Central Benefits National Life Insurance, a health and life insurance company based in Westerville, OH. The transaction closed on July 31, 2009.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Puneet Bhullar, MD Po Box 1008, Olympia, WA 98507-1008 Ph: (360) 413-8413 | Puneet Bhullar, MD 615 Lilly Rd Ne Ste 200, Olympia, WA 98506 Ph: (360) 413-8413 |
News Archive
Out of a library with billions of artificial antibodies, researchers have identified ten that can possibly prevent cancer tumours from growing.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter's Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.
SeeChange Health, the nation's only fully-insured, value-based health insurance provider, announced today the acquisition of Central Benefits National Life Insurance, a health and life insurance company based in Westerville, OH. The transaction closed on July 31, 2009.
› Verified 9 days ago
Elizabeth A Howell, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 | |
Dr. Thomas Wu, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 404 Black Hills Ln Sw, Suite C, Olympia, WA 98502 Phone: 360-754-0660 Fax: 360-754-0139 | |
Leah Ann Miller, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 525 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-493-7230 | |
Ms. Laurel A Dickason, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3920 Capitol Mall Dr Sw, Ste 400, Olympia, WA 98502 Phone: 360-705-1259 Fax: 360-705-2757 | |
Melanie L Andersen, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 Fax: 360-923-7089 | |
Dr. Sara Dawn Patt O'dell, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 |